Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive/HER2-positive breast cancer - The TOUCH trial

被引：0
|
作者：
Biganzoli, Laura
Brain, Etienne
Malorni, Luca
Gombos, Andrea
Hasler-Strub, Ursula
Zamagni, Claudio
Chakiba, Camille
Roschitzki-Voser, Heidi
Regan, Meredith M.
机构：
[1] Int Breast Canc Study Grp, Bern, Switzerland
[2] TOUCH Investigators, Bern, Switzerland
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT-28-02
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
  • [42] Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers
    Fernandez, M.
    Martinez, N.
    Calvo, I.
    Garcia, E.
    Ugidos, L.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia, M.
    Suarez, A.
    Lopez-Rios, F.
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2013, 73
  • [43] Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer
    Shagisultanova, Elena
    Diamond, Jennifer
    Stopeck, Alison
    Pusztai, Lajos
    O'Regan, Ruth
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    McSpadden, Tessa
    Borakove, Michelle
    Shedin, Troy
    Kabos, Peter
    Borges, Virginia
    CANCER RESEARCH, 2018, 78 (04)
  • [44] Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)
    Fernandez, M.
    Calvo, I.
    Martinez, N.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia-Aranda, M.
    Suarez, A.
    -Rios, F. Lopez
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2012, 72
  • [45] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [46] A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
    Foukakis, T.
    Naume, B.
    Karakatsanis, A.
    Andersson, A.
    Barnekow, E.
    Kessler, L. Edman
    Einbeigi, Z.
    Engebraten, O.
    Killander, F.
    Linderholm, B. K.
    Schiza, A.
    Valachis, A.
    Bergh, J.
    Villacampa, G.
    Zouzos, A.
    Hellstrom, M.
    Hartman, J.
    Matikas, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S356 - S356
  • [47] Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
    Hussain, Nadia
    Said, Amira S. A.
    Khan, Zainab
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2018, 2018
  • [48] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Veeraraghavan, Jamunarani
    Gutierrez, Carolina
    Sethunath, Vidyalakshmi
    Mehravaran, Sepideh
    Giuliano, Mario
    Shea, Martin J.
    Mitchell, Tamika
    Wang, Tao
    Nanda, Sarmistha
    Pereira, Resel
    Davis, Robert
    Goutsouliak, Kristina
    Qin, Lanfang
    De Angelis, Carmine
    Diala, Irmina
    Lalani, Alshad S.
    Nagi, Chandandeep
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    NPJ BREAST CANCER, 2021, 7 (01)
  • [49] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Bianchini, Giampaolo
    Kiermaier, Astrid
    Bianchi, Giulia Valeria
    Im, Young-Hyuck
    Pienkowski, Tadeusz
    Liu, Mei-Ching
    Tseng, Ling-Ming
    Dowsett, Mitch
    Zabaglo, Lila
    Kirk, Sarah
    Szado, Tania
    Eng-Wong, Jennifer
    Amler, Lukas C.
    Valagussa, Pinuccia
    Gianni, Luca
    BREAST CANCER RESEARCH, 2017, 19
  • [50] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
12345